MedPage Today brought together three expert leaders for a virtual roundtable discussion on the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and ...
The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...
- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...
New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in multiple sclerosis (MS). PRLs are thought to capture a subset of chronic ...
Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...
The use of ibudilast in the treatment of progressive multiple sclerosis (MS) has been suggested to reduce lesion volume in patients. Ibudilast intervention in patients with progressive multiple ...
Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many ...
ETHealthworld.com brings latest multiple sclerosis news, views and updates from all top sources for the Indian Health industry.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback